At the end of the session, participants will be able to:
1. Discuss how care of NSCLC patients has changed from a biomarker testing and treatment perspective
2. Discuss anticipated ongoing impacts to patient care over the next year
3. Discuss how best to normalize and ensure access to testing and treatment are maintained
Dr. Parneet Cheema CHEEMA, HBSC, MD, MBIOTECH, FRCPC, medical oncologist @ William Osler Health System, Brampton/Toronto sites; focused on lung cancer and immunotherapy.
Dr. Brandon Sheffield, Anatomic & Molecular Pathologist, Medical Director, Immunohistochemistry & Molecular Pathology, physician lead of research @William Osler Health System
Host: Anna Plotkin, OAP President
Target audience: Pathologists, Resident, Medical Student, Pathologists' Assistants
CanMEDS Role: Medical Expert, Communicator, Collaborator, Leader, Professional
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the CAP-ACP. You may claim a maximum of 1.0 hours per event attended. (credits are automatically calculated).
This webinar is co-developed with EMD Serono, Pfizer and OAP was planned to achieve scientific integrity, objectivity and balance.
The physician organization (OAP) has ultimate authority over all decisions and is accountable to ensure that the administrative, educational and ethical accreditation standards for group learning activities are met.